ID

39344

Description

Paclitaxel, Carboplatin and Cetuximab (PCC) Versus Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC); ODM derived from: https://clinicaltrials.gov/show/NCT01154920

Link

https://clinicaltrials.gov/show/NCT01154920

Keywords

Versions (1)
  1. 12/23/19 12/23/19 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

December 23, 2019

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Head and Neck Squamous Cell Carcinoma NCT01154920

English

Eligibility Head and Neck Squamous Cell Carcinoma NCT01154920

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. patients with biopsy-proven squamous cell carcinoma of the oropharynx, oral cavity, nasopharynx, hypopharynx, or larynx.
Description

Squamous cell carcinoma of oropharynx | Squamous cell carcinoma of mouth | Squamous cell carcinoma of nasopharynx | Squamous cell carcinoma of the hypopharynx | Laryngeal Squamous Cell Carcinoma

Data type

boolean

Alias
UMLS CUI [1]
C0280313
UMLS CUI [2]
C0585362
UMLS CUI [3]
C0279698
UMLS CUI [4]
C0280321
UMLS CUI [5]
C0280324
2. biopsy material sufficient for hpv status determination available
Description

Biopsy Tissue material Sufficient | Human Papillomavirus Determination

Data type

boolean

Alias
UMLS CUI [1,1]
C0005558
UMLS CUI [1,2]
C0457457
UMLS CUI [1,3]
C0205410
UMLS CUI [2,1]
C0021344
UMLS CUI [2,2]
C1148554
3. patients should have stage iv disease, stage t0-4 n2b-2c/3 m0 (for nasopharynx patients, stage n1 is eligible). measurable disease in either the t or n site by recist is required.
Description

Disease TNM clinical staging | Measurable Disease Primary tumor Site | Measurable Disease Lymph node Site

Data type

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C3258246
UMLS CUI [2,1]
C1513041
UMLS CUI [2,2]
C0677930
UMLS CUI [2,3]
C1515974
UMLS CUI [3,1]
C1513041
UMLS CUI [3,2]
C0024204
UMLS CUI [3,3]
C1515974
4. patients with stage tx primary disease are eligible if there is n2b-c/3 lymphadenopathy
Description

Disease TNM clinical staging | Lymphadenopathy

Data type

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C3258246
UMLS CUI [2]
C0497156
5. ecog ps 0-1
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
6. age >/= 18 years
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
7. patients should have adequate bone marrow function defined as an absolute peripheral granulocyte count (agc >/= 1500 cells/mm^3 and platelet count >/= 100,000 cells/mm^3; adequate hepatic function with bilirubin </= uln (excluding gilbert's disease), ast and alt may be up to 2.5 x uln if alkaline phosphatase is normal. alkaline phosphatase may be up to 4 x uln if ast and alt are normal. in determining eligibility the more abnormal of the two values (ast or alt) should be used.
Description

Bone Marrow function | Absolute neutrophil count | Platelet Count measurement | Liver function | Serum total bilirubin measurement | Gilbert Disease Excluded | Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Alkaline phosphatase measurement

Data type

boolean

Alias
UMLS CUI [1,1]
C0005953
UMLS CUI [1,2]
C0031843
UMLS CUI [2]
C0948762
UMLS CUI [3]
C0032181
UMLS CUI [4]
C0232741
UMLS CUI [5]
C1278039
UMLS CUI [6,1]
C0017551
UMLS CUI [6,2]
C0332196
UMLS CUI [7]
C0201899
UMLS CUI [8]
C0201836
UMLS CUI [9]
C0201850
8. creatinine clearance >/=40 ml/min determined by 24 hour collection or nomogram:crcl male = (140 - age) x (wt in kg)/serum cr x 72 or crcl female = 0.85 x (crcl male)
Description

Creatinine clearance measurement | Gender

Data type

boolean

Alias
UMLS CUI [1]
C0373595
UMLS CUI [2]
C0079399
9. patients should have no serious acute or chronic co-morbid condition, or acute infection, which in the judgment of the attending physician would affect administration of the induction chemotherapy regimens.
Description

Comorbidity Serious Absent | Comorbidity chronic Absent | Communicable Disease Absent | Communicable Disease Affecting Induction Chemotherapy

Data type

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0205404
UMLS CUI [1,3]
C0332197
UMLS CUI [2,1]
C0009488
UMLS CUI [2,2]
C0205191
UMLS CUI [2,3]
C0332197
UMLS CUI [3,1]
C0009450
UMLS CUI [3,2]
C0332197
UMLS CUI [4,1]
C0009450
UMLS CUI [4,2]
C0392760
UMLS CUI [4,3]
C3179010
10. patients must sign a study-specific informed consent form
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. histology other than squamous cell carcinoma
Description

Histology Except Squamous cell carcinoma

Data type

boolean

Alias
UMLS CUI [1,1]
C0344441
UMLS CUI [1,2]
C0332300
UMLS CUI [1,3]
C0007137
2. proven distant metastases (below the clavicle) by clinical or radiographic measures
Description

Distant metastasis below Clavicle

Data type

boolean

Alias
UMLS CUI [1,1]
C1269798
UMLS CUI [1,2]
C0542339
UMLS CUI [1,3]
C0008913
3. ecog>1
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
4. prior chemotherapy, within the previous 3 years
Description

Prior Chemotherapy

Data type

boolean

Alias
UMLS CUI [1]
C1514457
5. prior radiotherapy to the head and neck
Description

Radiation therapy to the head and neck

Data type

boolean

Alias
UMLS CUI [1]
C4540910
6. prior cetuximab therapy or prior therapy with any other drug that targets the egfr pathway
Description

cetuximab | Targeted Therapy EGFR signaling pathway

Data type

boolean

Alias
UMLS CUI [1]
C0995188
UMLS CUI [2,1]
C2985566
UMLS CUI [2,2]
C1155379
7. initial surgical resection rendering the patient clinically and radiologically disease free
Description

Excision Initial | Patient Disease Free

Data type

boolean

Alias
UMLS CUI [1,1]
C0728940
UMLS CUI [1,2]
C0205265
UMLS CUI [2,1]
C0030705
UMLS CUI [2,2]
C0012634
UMLS CUI [2,3]
C0332296
8. simultaneous primary invasive cancers, excluding superficial non-melanoma skin cancers
Description

Primary tumor Invasive Simultaneous | Exception Skin carcinoma Superficial

Data type

boolean

Alias
UMLS CUI [1,1]
C0677930
UMLS CUI [1,2]
C0205281
UMLS CUI [1,3]
C0521115
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0699893
UMLS CUI [2,3]
C0205124
9. patients with a history of another malignancy (excluding non melanoma skin cancers, and cancers treated > 3 years prior for which patient remains continuously disease free
Description

Cancer Other | Exception Skin carcinoma | Exception Malignant Neoplasm Treated | Exception Disease Free

Data type

boolean

Alias
UMLS CUI [1]
C1707251
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0699893
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0006826
UMLS CUI [3,3]
C1522326
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0012634
UMLS CUI [4,3]
C0332296
10. men and women of childbearing potential (wocbp) unwilling to consent to using effective contraception while on treatment and for at least 3 months thereafter
Description

Females & males of reproductive potential Contraceptive methods Unwilling

Data type

boolean

Alias
UMLS CUI [1,1]
C4034483
UMLS CUI [1,2]
C0700589
UMLS CUI [1,3]
C0558080
11. women who are pregnant or breastfeeding
Description

Pregnancy | Breast Feeding

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
12. pre-existing peripheral neuropathy ctcae grade 2 or worse
Description

Peripheral Neuropathy Pre-existing CTCAE grades

Data type

boolean

Alias
UMLS CUI [1,1]
C0031117
UMLS CUI [1,2]
C2347662
UMLS CUI [1,3]
C1516728
13. hemoglobin < 8.0g/dl
Description

Hemoglobin measurement

Data type

boolean

Alias
UMLS CUI [1]
C0518015
14. patients with a history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80
Description

Severe allergy Docetaxel | Severe allergy Formulation Polysorbate 80

Data type

boolean

Alias
UMLS CUI [1,1]
C2945656
UMLS CUI [1,2]
C0246415
UMLS CUI [2,1]
C2945656
UMLS CUI [2,2]
C0524527
UMLS CUI [2,3]
C0032601
Back to the top of the page

Similar models

Eligibility Head and Neck Squamous Cell Carcinoma NCT01154920

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Squamous cell carcinoma of oropharynx | Squamous cell carcinoma of mouth | Squamous cell carcinoma of nasopharynx | Squamous cell carcinoma of the hypopharynx | Laryngeal Squamous Cell Carcinoma
Item
1. patients with biopsy-proven squamous cell carcinoma of the oropharynx, oral cavity, nasopharynx, hypopharynx, or larynx.
boolean
C0280313 (UMLS CUI [1])
C0585362 (UMLS CUI [2])
C0279698 (UMLS CUI [3])
C0280321 (UMLS CUI [4])
C0280324 (UMLS CUI [5])
Biopsy Tissue material Sufficient | Human Papillomavirus Determination
Item
2. biopsy material sufficient for hpv status determination available
boolean
C0005558 (UMLS CUI [1,1])
C0457457 (UMLS CUI [1,2])
C0205410 (UMLS CUI [1,3])
C0021344 (UMLS CUI [2,1])
C1148554 (UMLS CUI [2,2])
Disease TNM clinical staging | Measurable Disease Primary tumor Site | Measurable Disease Lymph node Site
Item
3. patients should have stage iv disease, stage t0-4 n2b-2c/3 m0 (for nasopharynx patients, stage n1 is eligible). measurable disease in either the t or n site by recist is required.
boolean
C0012634 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
C1513041 (UMLS CUI [2,1])
C0677930 (UMLS CUI [2,2])
C1515974 (UMLS CUI [2,3])
C1513041 (UMLS CUI [3,1])
C0024204 (UMLS CUI [3,2])
C1515974 (UMLS CUI [3,3])
Disease TNM clinical staging | Lymphadenopathy
Item
4. patients with stage tx primary disease are eligible if there is n2b-c/3 lymphadenopathy
boolean
C0012634 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
C0497156 (UMLS CUI [2])
ECOG performance status
Item
5. ecog ps 0-1
boolean
C1520224 (UMLS CUI [1])
Age
Item
6. age >/= 18 years
boolean
C0001779 (UMLS CUI [1])
Bone Marrow function | Absolute neutrophil count | Platelet Count measurement | Liver function | Serum total bilirubin measurement | Gilbert Disease Excluded | Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Alkaline phosphatase measurement
Item
7. patients should have adequate bone marrow function defined as an absolute peripheral granulocyte count (agc >/= 1500 cells/mm^3 and platelet count >/= 100,000 cells/mm^3; adequate hepatic function with bilirubin </= uln (excluding gilbert's disease), ast and alt may be up to 2.5 x uln if alkaline phosphatase is normal. alkaline phosphatase may be up to 4 x uln if ast and alt are normal. in determining eligibility the more abnormal of the two values (ast or alt) should be used.
boolean
C0005953 (UMLS CUI [1,1])
C0031843 (UMLS CUI [1,2])
C0948762 (UMLS CUI [2])
C0032181 (UMLS CUI [3])
C0232741 (UMLS CUI [4])
C1278039 (UMLS CUI [5])
C0017551 (UMLS CUI [6,1])
C0332196 (UMLS CUI [6,2])
C0201899 (UMLS CUI [7])
C0201836 (UMLS CUI [8])
C0201850 (UMLS CUI [9])
Creatinine clearance measurement | Gender
Item
8. creatinine clearance >/=40 ml/min determined by 24 hour collection or nomogram:crcl male = (140 - age) x (wt in kg)/serum cr x 72 or crcl female = 0.85 x (crcl male)
boolean
C0373595 (UMLS CUI [1])
C0079399 (UMLS CUI [2])
Comorbidity Serious Absent | Comorbidity chronic Absent | Communicable Disease Absent | Communicable Disease Affecting Induction Chemotherapy
Item
9. patients should have no serious acute or chronic co-morbid condition, or acute infection, which in the judgment of the attending physician would affect administration of the induction chemotherapy regimens.
boolean
C0009488 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
C0009488 (UMLS CUI [2,1])
C0205191 (UMLS CUI [2,2])
C0332197 (UMLS CUI [2,3])
C0009450 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
C0009450 (UMLS CUI [4,1])
C0392760 (UMLS CUI [4,2])
C3179010 (UMLS CUI [4,3])
Informed Consent
Item
10. patients must sign a study-specific informed consent form
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Histology Except Squamous cell carcinoma
Item
1. histology other than squamous cell carcinoma
boolean
C0344441 (UMLS CUI [1,1])
C0332300 (UMLS CUI [1,2])
C0007137 (UMLS CUI [1,3])
Distant metastasis below Clavicle
Item
2. proven distant metastases (below the clavicle) by clinical or radiographic measures
boolean
C1269798 (UMLS CUI [1,1])
C0542339 (UMLS CUI [1,2])
C0008913 (UMLS CUI [1,3])
ECOG performance status
Item
3. ecog>1
boolean
C1520224 (UMLS CUI [1])
Prior Chemotherapy
Item
4. prior chemotherapy, within the previous 3 years
boolean
C1514457 (UMLS CUI [1])
Radiation therapy to the head and neck
Item
5. prior radiotherapy to the head and neck
boolean
C4540910 (UMLS CUI [1])
cetuximab | Targeted Therapy EGFR signaling pathway
Item
6. prior cetuximab therapy or prior therapy with any other drug that targets the egfr pathway
boolean
C0995188 (UMLS CUI [1])
C2985566 (UMLS CUI [2,1])
C1155379 (UMLS CUI [2,2])
Excision Initial | Patient Disease Free
Item
7. initial surgical resection rendering the patient clinically and radiologically disease free
boolean
C0728940 (UMLS CUI [1,1])
C0205265 (UMLS CUI [1,2])
C0030705 (UMLS CUI [2,1])
C0012634 (UMLS CUI [2,2])
C0332296 (UMLS CUI [2,3])
Primary tumor Invasive Simultaneous | Exception Skin carcinoma Superficial
Item
8. simultaneous primary invasive cancers, excluding superficial non-melanoma skin cancers
boolean
C0677930 (UMLS CUI [1,1])
C0205281 (UMLS CUI [1,2])
C0521115 (UMLS CUI [1,3])
C1705847 (UMLS CUI [2,1])
C0699893 (UMLS CUI [2,2])
C0205124 (UMLS CUI [2,3])
Cancer Other | Exception Skin carcinoma | Exception Malignant Neoplasm Treated | Exception Disease Free
Item
9. patients with a history of another malignancy (excluding non melanoma skin cancers, and cancers treated > 3 years prior for which patient remains continuously disease free
boolean
C1707251 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0699893 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0006826 (UMLS CUI [3,2])
C1522326 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C0012634 (UMLS CUI [4,2])
C0332296 (UMLS CUI [4,3])
Females & males of reproductive potential Contraceptive methods Unwilling
Item
10. men and women of childbearing potential (wocbp) unwilling to consent to using effective contraception while on treatment and for at least 3 months thereafter
boolean
C4034483 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C0558080 (UMLS CUI [1,3])
Pregnancy | Breast Feeding
Item
11. women who are pregnant or breastfeeding
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Peripheral Neuropathy Pre-existing CTCAE grades
Item
12. pre-existing peripheral neuropathy ctcae grade 2 or worse
boolean
C0031117 (UMLS CUI [1,1])
C2347662 (UMLS CUI [1,2])
C1516728 (UMLS CUI [1,3])
Hemoglobin measurement
Item
13. hemoglobin < 8.0g/dl
boolean
C0518015 (UMLS CUI [1])
Severe allergy Docetaxel | Severe allergy Formulation Polysorbate 80
Item
14. patients with a history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80
boolean
C2945656 (UMLS CUI [1,1])
C0246415 (UMLS CUI [1,2])
C2945656 (UMLS CUI [2,1])
C0524527 (UMLS CUI [2,2])
C0032601 (UMLS CUI [2,3])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial